KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS.[1] It belongs to the class of nucleoside reverse transcriptase inhibitors.[2]

KP-1461 is a prodrug of the active antiviral agent KP-1212.[3]

References

  1. ↑ "KP-1461". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-09-04.
  2. ↑ Harris K, Sergueev D, Reno J (December 2006). "The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy". Retrovirology. 3 (Suppl 1) S13. doi:10.1186/1742-4690-3-S1-S13. PMC 1716920.
  3. ↑ "KP-1461". DrugBank. Canadian Institutes of Health Research.
source: https://en.wikipedia.org/wiki/KP-1461